AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2017

Oct 3, 2017

30583_dirs_2017-10-02_85657123-06c9-483d-a609-b807353f5d6c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2017-09-28

Reporting Person: BAFFI ROBERT (EVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-28	Common Stock	S	15500	$92.4952	Disposed	129083	Direct
2017-09-28	Common Stock	S	2915	$92.06	Disposed	28761	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017.

F2: The price in column 4 is the weighted average price. The price actually received ranged from $91.92 to $92.90. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F3: All shares sold at the same price.